Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Alberta
$27,000.00
Nasal cytokines as predictive biomarkers of biologic response in chronic rhinosinusitis
FY 2025-26
Summary
Nasal airway epithelia and innate immune cells play an integral role in triggering diseases, such as chronic rhinosinusitis (CRS), through the production of various pro-inflammatory cytokines. Patients who suffer from persistent disease despite medical and surgical management are initiated on biologic therapies that target these inflammatory molecules. However, cytokine levels are not measured in patients, which may prevent patients from initiating specific biologics best targeted to their underlying inflammatory profile. Furthermore, some patients do not respond well to a specific biologic, necessitating them to switch therapies. As there is no standardized approach to predict treatment success and monitor response at a cellular level, the duration of therapy remains up to prescriber judgement. With the impending proliferation of biologics available and under development, prescription decision-making will become challenging for physicians. This raises the potential for a non-invasive sampling approach to provide a practical method to assess cytokine expression in patients embarking on biologic therapy. This prospective study aims to use nasal swabs to quantify alarmin cytokine expression before and after initiation of biologic therapy in patients with CRS. Here, we will collect swabs at baseline, 3- and 6-months post-treatment. Assays will be used to quantify cytokine levels, and data will be correlated with a validated symptom questionnaire and endoscopic grading of the disease. We predict that with the initiation of biologic therapy, the cytokine levels will decrease and patient symptoms will improve. This study highlights the potential for an in-clinic swab to guide biologic selection and monitoring for improved patient outcomes and reduced health care costs.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572890
Name
Almas Sarah
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Nasal cytokines as predictive biomarkers of biologic response in chronic rhinosinusitis
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Alarmins; Biologics; Biomarkers; Chronic; Cytokines; Inflammation; Nasal Swabs; Personalized Medicine; Rhinosinusitis; Symptom Severity
Abstract
Nasal airway epithelia and innate immune cells play an integral role in triggering diseases, such as chronic rhinosinusitis (CRS), through the production of various pro-inflammatory cytokines. Patients who suffer from persistent disease despite medical and surgical management are initiated on biologic therapies that target these inflammatory molecules. However, cytokine levels are not measured in patients, which may prevent patients from initiating specific biologics best targeted to their underlying inflammatory profile. Furthermore, some patients do not respond well to a specific biologic, necessitating them to switch therapies. As there is no standardized approach to predict treatment success and monitor response at a cellular level, the duration of therapy remains up to prescriber judgement. With the impending proliferation of biologics available and under development, prescription decision-making will become challenging for physicians. This raises the potential for a non-invasive sampling approach to provide a practical method to assess cytokine expression in patients embarking on biologic therapy. This prospective study aims to use nasal swabs to quantify alarmin cytokine expression before and after initiation of biologic therapy in patients with CRS. Here, we will collect swabs at baseline, 3- and 6-months post-treatment. Assays will be used to quantify cytokine levels, and data will be correlated with a validated symptom questionnaire and endoscopic grading of the disease. We predict that with the initiation of biologic therapy, the cytokine levels will decrease and patient symptoms will improve. This study highlights the potential for an in-clinic swab to guide biologic selection and monitoring for improved patient outcomes and reduced health care costs.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Almas, Sarah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~